Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2012 Financial Results
February 20 2013 - 11:00AM
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, will report financial results for the
fourth quarter and fiscal year 2012 on Tuesday, March 5, 2013. The
Company has scheduled a conference call for that same day, Tuesday,
March 5, 2013 at 11:00am EST (4:00pm GMT) to discuss the results of
the quarter.
Interested parties can access the
call by dialing: |
USA: |
1-877-317-6789 |
International: |
1-412-317-6789 |
Conference ID #: |
10025641 |
|
|
A simultaneous webcast of the
call can be accessed at: |
http://www.videonewswire.com/event.asp?id=92502 |
|
|
A replay of the call can be
accessed until March 12, 2013 by dialing: |
|
|
USA: |
1-877-344-7529 |
International: |
1-412-317-0088 |
Conference ID #: |
10025641 |
|
|
The webcast of the call will be
available for 30 days at: |
http://www.videonewswire.com/event.asp?id=92502 |
About Trinity Biotech plc
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
The Trinity Biotech plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10602
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
CONTACT: Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2023 to Mar 2024